Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,818 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Kidney Cancers Clear all

Conditions: Renal Cell Carcinoma, Hypertension, Melanoma, Cancer
Interventions: Ambulatory Blood Pressure Measurement; Diagnostic Test
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 40 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma, Wilms Tumor, Rhabdoid Tumor, Carcinoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, Clear Cell Sarcoma, Malignant Peripheral Nerve Sheath Tumors, Desmoplastic Small Round Cell Tumor, Soft Tissue Sarcoma, Neuroblastoma
Interventions: second generation 4-1BBζ EGFR806-EGFRt, second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG; Biological
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 1 Year to 30 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2040
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Multiple Myeloma, Monoclonal Gammopathy of Renal Significance
Interventions: Cyclophosphamide, Bortezomib, Dexamethasone, Daratumumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 11
States / cities: Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more

Conditions: Multiple Myeloma
Interventions: Cyclophosphamide, Ciltacabtagene Autoleucel, Total body irradiation; Drug · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma of Head and Neck, Triple-Negative Breast Cancer, Urothelial Carcinoma, Cholangiocarcinoma, GastroEsophageal Cancer, Pancreatic Cancer, Sarcoma
Interventions: Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120, Part 4 TPST-1120 + nivolumab; Drug
Lead sponsor: Tempest Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 11
States / cities: San Francisco, California • Miami, Florida • Baltimore, Maryland + 7 more

Conditions: Renal Cell Carcinoma
Interventions: Stereotactic ablative radiation therapy; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Advanced Melanoma, Non-small Cell Lung Cancer, Renal Cell Carcinoma
Interventions: APX005M, Cabiralizumab, Nivolumab; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Carcinoma, Renal Cell, Kidney Disease, Kidney Cancer
Interventions: Sorafenib; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Renal Cell Carcinoma
Interventions: Entinostat, Nivolumab, Ipilimumab; Drug
Lead sponsor: Roberto Pili; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Indianapolis, Indiana

Conditions: Carcinoma, Renal Cell
Interventions: combination of gemcitabine, capecitabine, and bevacizumab; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Advanced Cancer, Clear Cell Renal Cell Carcinoma
Interventions: 177Lu girentuximab, Nivolumab, Cabozantinib, ArabinoFuranosylGuanine [18F]F-AraG; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Renal Cell Carcinoma
Interventions: CTT1057; Drug
Lead sponsor: Cancer Targeted Technology; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Lung Cancer, Squamous Cell Carcinoma, Head and Neck Cancer, Hepatic Carcinoma, Renal Cell Carcinoma
Interventions: [F-18] VM4-037; Drug
Lead sponsor: Siemens Molecular Imaging; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Renal Cell Cancer
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 664 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Type 2 Diabetes Mellitus, Obesity
Interventions: Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention; Procedure · Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 25 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cancer, Immunotherapy, Advanced Solid Tumors Cancer, Bladder Cancer, TNBC, Triple Negative Breast Cancer, Colorectal Cancer, DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer, NSCLC (Non-small-cell Lung Cancer), Skin Cancer, Melanoma (Skin Cancer)
Interventions: Biopsy; Procedure
Lead sponsor: Elephas; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2038
U.S. locations: 8
States / cities: Fort Smith, Arkansas • Frederick, Maryland • Springfield, Missouri + 4 more

Conditions: Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Renal Pelvis and Ureter Cancer AJCC v7
Interventions: Best Practice, Biospecimen Collection, Central Venous Cannula Insertion, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab, Plasmapheresis, Positron Emission Tomography, Questionnaire Administration, Antibody-Drug Conjugate Therapy; Other · Procedure · Drug + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer, CRC, RCC, ccRCC
Interventions: CB-839, Talazoparib; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 6 more

Conditions: Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
Interventions: HLX17, US-sourced Keytruda®; Drug
Lead sponsor: Shanghai Henlius Biotech; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 12
States / cities: Glendale, California • Los Alamitos, California • Los Angeles, California + 8 more

Conditions: Urothelial Carcinoma
Interventions: Ramucirumab, Docetaxel, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 33
States / cities: Fayetteville, Arkansas • Fullerton, California • Los Angeles, California + 28 more

Conditions: Cerebral Vein Thrombosis, Deep Vein Thrombosis, Gonadal Thrombosis, Hepatic Thrombosis, Malignant Neoplasm, Mesenteric Thrombosis, Metastatic Malignant Neoplasm, Portal Vein Thrombosis, Pulmonary Embolism, Renal Vein Thrombosis, Splenic Thrombosis, Venous Thromboembolism
Interventions: Apixaban, Dalteparin, Questionnaire Administration; Drug · Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 18
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Evanston, Illinois + 15 more

Conditions: Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
Interventions: Durvalumab, Tremelimumab, Cisplatin + Gemcitabine, Carboplatin + Gemcitabine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Bakersfield, California • Fullerton, California + 19 more

Conditions: Carcinoma, Renal Cell
Interventions: Pembrolizumab, MK-4830, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab, Favezelimab/Pembrolizumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 11
States / cities: San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 7 more

Conditions: Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor, Stage IV Mixed Cell Type Kidney Wilms Tumor
Interventions: Bone Scan, Carboplatin, Computed Tomography, Cyclophosphamide, Dactinomycin, Doxorubicin, Etoposide, Irinotecan, Magnetic Resonance Imaging, Nephrectomy, Patient Observation, Positron Emission Tomography, Ultrasound Imaging, Vincristine, X-Ray Imaging; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 1,656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 154
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 129 more

Search by objective public record fields.

Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease

EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC

APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma

Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer

Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma

A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma

An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037

Urine Proteome of Surgical Patients and Healthy Volunteers

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)